StreetInsider.com News Articles

Form SCHEDULE 13G/A uniQure N.V. Filed by: JPMORGAN CHASE & CO

Fri, 16 Oct 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20261016/27197493.html

uniQure BV (QURE) PT Raised to $48 at UBS

Thu, 15 Oct 2026 09:17:42 -0400

UBS analyst Joon Lee raised the price target on uniQure BV (NASDAQ: QURE) to $48.00 (from $27.00) while maintaining a Buy rating.

Barclays Downgrades uniQure BV (QURE) to Equalweight

Mon, 05 Oct 2026 08:00:35 -0400

Barclays analyst Eliana Merle downgraded uniQure BV (NASDAQ: QURE) from Overweight to Equalweight with a price target of $28.00 (from $60.00).

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $23.46 yesterday.

uniQure BV (QURE) PT Lowered to $48 at RBC Capital

Fri, 02 Oct 2026 05:15:01 -0400

RBC Capital analyst Luca Issi lowered the price target on uniQure BV (NASDAQ: QURE) to $48.00 (from $65.00) while maintaining a Outperform rating.

The analyst comments "Our view: We hosted the C-suite for an in person NDR in Boston (CEO, CMO, CCO and IR). On recent data, we appreciate that the p-value for cUHDRS missed the stats at 4 years (p=0.144), but we think the team did a great job articulating some of the limitations of that analysis including the control arm impacted by survivor bias, missing data and possibly covid. Importantly, the totality of the evidence continues to suggest a

uniQure BV (QURE) PT Lowered to $48 at RBC Capital

Fri, 02 Oct 2026 05:15:01 -0400

RBC Capital analyst Luca Issi lowered the price target on uniQure BV (NASDAQ: QURE) to $48.00 (from $65.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)

Wed, 30 Sep 2026 07:15:44 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on uniQure BV (NASDAQ: QURE).

The analyst commented: "AMT-130’s four-year cUHDRS result complicates the durability case, although the sustained TFC benefit and the three-year data underlying the submitted BLA remain encouraging. In 12 high-dose patients, the prespecified four-year cUHDRS analysis showed 44% slowing versus an updated external control but missed nominal statistical significance (p=0.144). However, Total Functional Capacity (TFC) showed 61% slowing (nominal p=0.008), which management and a treating clinician emphasized reflects patients’ ability to work, manage finances, and live independently, making its sustained four-year benefit an important

uniQure BV (QURE) PT Lowered to $31 at Goldman Sachs

Wed, 30 Sep 2026 06:52:05 -0400

Goldman Sachs analyst Salveen Richter lowered the price target on uniQure BV (NASDAQ: QURE) to $31.00 (from $46.00) while maintaining a Neutral rating.

QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.

Tue, 29 Sep 2026 11:00:00 -0400

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).

On September 29, 2026, uniQure's shares declined significantly after the Company reported updated 48-month data for ifezuntirgene inilparvovec, also known as AMT-130, its investigational gene therapy for Huntington’s disease.

On this news, uniQure's stock price was down more than 35% during intraday trading on September 29, 2026.

uniQure Investors: If you purchased uniQure stock and suffered financial losses, you are

QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.

Tue, 29 Sep 2026 11:00:00 -0400

On this news, uniQure's stock price was down more than 35% during intraday trading on September 29, 2026.

uniQure Investors: If you purchased uniQure stock and suffered financial losses, you are

Form 8-K uniQure N.V. For: Sep 29

Tue, 29 Sep 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260929/27118690.html

Stifel Reiterates Buy Rating on uniQure BV (QURE)

Tue, 29 Sep 2026 08:17:07 -0400

Stifel analyst Paul Matteis reiterated a Buy rating on uniQure BV (NASDAQ: QURE).

The analyst comments "We're reiterating our Buy rating on QURE on the back of updated ph1/2 data for AMT-130 in Huntington's Disease. Most importantly, the 3-year data, after including 3 additional patients where results have matured, continues to look robust, now showing 80% diseases slowing on cUHDRS and 67% slowing on TFC as compared to natural history. Both of these are slight improvements vs. the prior data cut, and each are statistically significant. Meanwhile, QURE also disclosed 4-year data for 12 patients--this continues to clearly support a drug

uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat

Tue, 29 Sep 2026 07:58:06 -0400

Investing.com -- Shares of gene therapy developer uniQure N.V. (NASDAQ: QURE) cratered 64% Tuesday morning following an updated data readout for its experimental Huntington’s disease treatment, ifezuntirgene inilparvovec (AMT-130). While the treatment continued to show a dose-dependent slowing of disease progression, a failure to hit statistical significance on a primary clinical measure at 48 months triggered a massive sell-off.

The severe market reaction hinged directly on the four-year data from 12 high-dose patients. The composite Unified Huntington’s Disease Rating Scale (cUHDRS)—a standard measure of cognitive, motor, and functional decline—showed a 44% slowing of disease progression compared to an external control

uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat

Tue, 29 Sep 2026 07:58:06 -0400

Uniqure Shares Drop 69% As Study Data Disappoint

Tue, 29 Sep 2026 07:13:16 -0400

(Updated - September 29, 2026 7:13 AM EDT)